Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013

International Journal of COPD

Volumn 10, Issue , 2015, Pages 925-937

  Raluy Callado, Mireia ^a   Lambrelli, Dimitra ^a   Maclachlan, Sharon ^a   Khalid, Javaria Mona ^b  

^a EVIDERA   (United Kingdom)

^b Takeda Global Research and Development Centre Europe   (United Kingdom)

Author keywords

COPD; GOLD 2013; Incidence; Prevalence; Primary care management

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; METHYLXANTHINE DERIVATIVE; SHORT ACTING DRUG; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE 2013 CLASSIFICATION; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; MONOTHERAPY; OBSERVATIONAL STUDY; PREVALENCE; RESPIRATORY TRACT DISEASE ASSESSMENT; RETROSPECTIVE STUDY; SMOKING; UNITED KINGDOM; AGE; COMBINATION DRUG THERAPY; DECISION SUPPORT SYSTEM; DISEASE COURSE; DRUG EFFECTS; DYSPNEA; FACTUAL DATABASE; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; COMORBIDITY; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; DYSPNEA; FEMALE; HUMANS; INCIDENCE; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84929417251     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S82064     Document Type: Article

References (32)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD; 2013. Available from: http://www.goldcopd.org/. Accessed January 29, 2014.
2. National Institute for Health and Care Excellence (NICE). National Clinical Guideline Centre for Acute and Chronic Conditions. Chronic Obstructive Pulmonary Disease. Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care; 2010. Available from: http://guidance.nice.org.uk/cg101/guidance/pdf/english. Accessed January 29, 2014.
3. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2010;19(1):57–61.
4. Rodriguez LA, Wallander MA, Martin-Merino E, Johansson S. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med. 2010;104(11):1691–1699.
5. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol. 2010;25(4):253–260.
6. Simpson CR, Hippisley-Cox J, Sheikh A. Trends in the epidemiology of chronic obstructive pulmonary disease in England: a national study of 51 804 patients. Br J Gen Pract. 2010;60(576):277–284.
7. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax. 2006;61(12):1043–1047.
8. Punekar YS, Shukla A, Mullerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65–73.
9. World Health Organization (WHO). The 10 Leading Causes of Death in the World 2000 and 2012. Fact sheet No 310; 2014. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed June 11, 2014.
10. Health and Social Care Information Centre. Quality and Outcomes Framework; 2014. Available from: http://www.hscic.gov.uk/gpes/qof. Accessed July 29, 2014.
11. hscic (Health & Social Care Information Centre). Indicators for Quality Improvement. 2014. Available from: http://www.hscic.gov.uk/iqi. Accessed July 29, 2014.
12. Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540.
13. Wurst KE, Shukla A, Muellerova H, Davis KJ. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study. COPD. 2014;11(5):521–530.
14. Thomas M, Radwan A, Stonham C, Marshall S. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD. 2014;11(3):300–309.
15. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):549–555.
16. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586.
17. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46(4):393–400.
18. Office of National Statistics (ONS). Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2011 and Mid-2012; 2013. Available from: http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/mid-2011-and-mid-2012/index.html. Accessed January 29, 2014.
19. James GPI, Donaldson G, Wedzicha W. P213 Longitudinal changes in the rate and mean age of incidence and prevalence of COPD in the UK, 2000–2009. Thorax. 2011;66(4):A154.
20. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341–1351.
21. Johns DP, Walters JA, Walters EH. Diagnosis and early detection of COPD using spirometry. J Thorac Dis. 2014;6(11):1557–1569.
22. Albers M, Schermer T, Molema J, et al. Do family physicians’ records fit guideline diagnosed COPD? Fam Pract. 2009;26(2):81–87.
23. van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ. 2002;324:1370.
24. Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J. 2014;43(4):993–1002.
25. Jones PW, Nadeau G, Small M, Adamek L. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Respir Med. 2014;108(1):129–135.
26. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888.
27. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686–689.
28. Leivseth L, Brumpton BM, Nilsen TI, Mai XM, Johnsen R, Langhammer A. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013;68(10):914–921.
29. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: epidemiology. Thorax. 2006;61(2):164–168.
30. Gruffydd-Jones K. GOLD guidelines 2011: what are the implications for primary care? Prim Care Respir J. 2012;21(4):437–441.
31. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–1097.
32. Global Initiative for Chronic Obstructive Lung Disease (GOLD). At-a-glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD); 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_AtAGlance:2015_Feb18.pdf